The U.S. Food and Drug Administration (FDA) has authorized Ocrevus Zunovo, a new subcutaneous injection, to treat relapsing and primary progressive multiple sclerosis (MS). This approval expands treatment options for MS patients, providing greater flexibility and accessibility.
Ocrevus Zunovo is a twice-a-year subcutaneous injection administered by a healthcare professional, offering an alternative to the existing intravenous (IV) formulation of Ocrevus. The safety and efficacy of Ocrevus Zunovo is supported by a decade of data from the IV formulation, with over 350,000 patients treated globally.
Clinical trials have demonstrated that Ocrevus Zunovo has a safety profile consistent with the IV formulation, demonstrating comparable suppression of relapse activity and MRI lesions. It has also been shown to be well-tolerated, with the most common side effects being injection reactions.
The approval of Ocrevus Zunovo not only provides another treatment option for MS patients but also addresses the need for flexibility and accessibility in the management of chronic conditions. By offering a subcutaneous injection option, Ocrevus Zunovo can be administered in settings where IV infrastructure may be limited, such as doctor’s offices, and can potentially reduce treatment time after the first dose.
This new treatment option empowers MS patients to make informed decisions about their care, ensuring that they have access to the most appropriate and convenient treatment approach. Ocrevus Zunovo is a significant advancement in MS management, offering greater flexibility and accessibility for patients seeking to improve their outcomes and quality of life.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
